These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
294 related articles for article (PubMed ID: 25422864)
1. Capping of aβ42 oligomers by small molecule inhibitors. Fu Z; Aucoin D; Ahmed M; Ziliox M; Van Nostrand WE; Smith SO Biochemistry; 2014 Dec; 53(50):7893-903. PubMed ID: 25422864 [TBL] [Abstract][Full Text] [Related]
2. High-resolution atomic force microscopy of soluble Abeta42 oligomers. Mastrangelo IA; Ahmed M; Sato T; Liu W; Wang C; Hough P; Smith SO J Mol Biol; 2006 Apr; 358(1):106-19. PubMed ID: 16499926 [TBL] [Abstract][Full Text] [Related]
3. Mechanism of Nucleated Conformational Conversion of Aβ42. Fu Z; Aucoin D; Davis J; Van Nostrand WE; Smith SO Biochemistry; 2015 Jul; 54(27):4197-207. PubMed ID: 26069943 [TBL] [Abstract][Full Text] [Related]
4. Sulindac Sulfide Induces the Formation of Large Oligomeric Aggregates of the Alzheimer's Disease Amyloid-β Peptide Which Exhibit Reduced Neurotoxicity. Prade E; Barucker C; Sarkar R; Althoff-Ospelt G; Lopez del Amo JM; Hossain S; Zhong Y; Multhaup G; Reif B Biochemistry; 2016 Mar; 55(12):1839-49. PubMed ID: 26900939 [TBL] [Abstract][Full Text] [Related]
6. Understanding amyloid fibril nucleation and aβ oligomer/drug interactions from computer simulations. Nguyen P; Derreumaux P Acc Chem Res; 2014 Feb; 47(2):603-11. PubMed ID: 24368046 [TBL] [Abstract][Full Text] [Related]
7. The conformational epitope for a new Aβ42 protofibril-selective antibody partially overlaps with the peptide N-terminal region. Colvin BA; Rogers VA; Kulas JA; Ridgway EA; Amtashar FS; Combs CK; Nichols MR J Neurochem; 2017 Dec; 143(6):736-749. PubMed ID: 28881033 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of Alzheimer's amyloid toxicity with a tricyclic pyrone molecule in vitro and in vivo. Hong HS; Rana S; Barrigan L; Shi A; Zhang Y; Zhou F; Jin LW; Hua DH J Neurochem; 2009 Feb; 108(4):1097-1108. PubMed ID: 19141069 [TBL] [Abstract][Full Text] [Related]
9. Key residues for the oligomerization of Aβ42 protein in Alzheimer's disease. Ngo S; Guo Z Biochem Biophys Res Commun; 2011 Oct; 414(3):512-6. PubMed ID: 21986527 [TBL] [Abstract][Full Text] [Related]
10. Solid-state NMR analysis of interaction sites of curcumin and 42-residue amyloid β-protein fibrils. Masuda Y; Fukuchi M; Yatagawa T; Tada M; Takeda K; Irie K; Akagi K; Monobe Y; Imazawa T; Takegoshi K Bioorg Med Chem; 2011 Oct; 19(20):5967-74. PubMed ID: 21924918 [TBL] [Abstract][Full Text] [Related]
11. Ferulic acid inhibits the transition of amyloid-β42 monomers to oligomers but accelerates the transition from oligomers to fibrils. Cui L; Zhang Y; Cao H; Wang Y; Teng T; Ma G; Li Y; Li K; Zhang Y J Alzheimers Dis; 2013; 37(1):19-28. PubMed ID: 23727899 [TBL] [Abstract][Full Text] [Related]
13. Design of LVFFARK and LVFFARK-functionalized nanoparticles for inhibiting amyloid β-protein fibrillation and cytotoxicity. Xiong N; Dong XY; Zheng J; Liu FF; Sun Y ACS Appl Mater Interfaces; 2015 Mar; 7(10):5650-62. PubMed ID: 25700145 [TBL] [Abstract][Full Text] [Related]
14. The coexistence of an equal amount of Alzheimer's amyloid-β 40 and 42 forms structurally stable and toxic oligomers through a distinct pathway. Chang YJ; Chen YR FEBS J; 2014 Jun; 281(11):2674-87. PubMed ID: 24720730 [TBL] [Abstract][Full Text] [Related]
15. Is the viscoelasticity of Alzheimer's Abeta42 peptide oligomers a general property of protein oligomers related to their toxicity? Saraiva AM; Pereira MC; Brezesinski G Langmuir; 2010 Jul; 26(14):12060-7. PubMed ID: 20515050 [TBL] [Abstract][Full Text] [Related]
16. Aβ(39-42) modulates Aβ oligomerization but not fibril formation. Gessel MM; Wu C; Li H; Bitan G; Shea JE; Bowers MT Biochemistry; 2012 Jan; 51(1):108-17. PubMed ID: 22129303 [TBL] [Abstract][Full Text] [Related]
17. Functional Characteristics and Molecular Mechanism of a New scFv Antibody Against Aβ42 Oligomers and Immature Protofibrils. Zhang Y; Sun Y; Huai Y; Zhang YJ Mol Neurobiol; 2015 Dec; 52(3):1269-1281. PubMed ID: 25330935 [TBL] [Abstract][Full Text] [Related]
18. Inhibiting and Remodeling Toxic Amyloid-Beta Oligomer Formation Using a Computationally Designed Drug Molecule That Targets Alzheimer's Disease. Downey MA; Giammona MJ; Lang CA; Buratto SK; Singh A; Bowers MT J Am Soc Mass Spectrom; 2019 Jan; 30(1):85-93. PubMed ID: 29713966 [TBL] [Abstract][Full Text] [Related]
19. Dynamic micellar oligomers of amyloid beta peptides play a crucial role in their aggregation mechanisms. Morel B; Carrasco MP; Jurado S; Marco C; Conejero-Lara F Phys Chem Chem Phys; 2018 Aug; 20(31):20597-20614. PubMed ID: 30059119 [TBL] [Abstract][Full Text] [Related]
20. Non-toxic conformer of amyloid β may suppress amyloid β-induced toxicity in rat primary neurons: implications for a novel therapeutic strategy for Alzheimer's disease. Izuo N; Murakami K; Sato M; Iwasaki M; Izumi Y; Shimizu T; Akaike A; Irie K; Kume T Biochem Biophys Res Commun; 2013 Aug; 438(1):1-5. PubMed ID: 23747423 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]